Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Amicus Therapeutics (FOLD) Accumulated Depreciation & Amortization (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Accumulated Depreciation & Amortization for 14 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization fell 12.72% year-over-year to $7.5 million, compared with a TTM value of $7.5 million through Dec 2025, down 12.72%, and an annual FY2025 reading of $7.5 million, down 12.72% over the prior year.
  • Accumulated Depreciation & Amortization was $7.5 million for Q4 2025 at Amicus Therapeutics, up from $5.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $8.5 million in Q4 2024 and bottomed at $1.3 million in Q1 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $4.1 million, with a median of $3.7 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization surged 87.94% in 2021, then plummeted 36.99% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $6.2 million in 2021, then dropped by 13.96% to $5.3 million in 2022, then skyrocketed by 47.38% to $7.9 million in 2023, then grew by 8.56% to $8.5 million in 2024, then fell by 12.72% to $7.5 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for FOLD at $7.5 million in Q4 2025, $5.6 million in Q3 2025, and $1.9 million in Q2 2025.